Angiotensin II for the Treatment of Vasodilatory Shock
Author(s) -
Ashish K. Khanna,
Shane English,
Xueyuan S. Wang,
Kealy R. Ham,
James A. Tumlin,
Harold M. Szerlip,
Laurence W. Busse,
Laith Altaweel,
Timothy E. Albertson,
Caleb Mackey,
Michael T. McCurdy,
David W. Boldt,
Stefan Chock,
Paul J. Young,
Kenneth Krell,
Richard G. Wunderink,
Marlies Ostermann,
Raghavan Murugan,
Michelle N. Gong,
Rakshit Panwar,
Johanna Hästbacka,
Raphaël Favory,
Balasubramanian Venkatesh,
Bruce Thompson,
Rinaldo Bellomo,
Jeffrey Jensen,
Stew Kroll,
Lakhmir S. Chawla,
George F. Tidmarsh,
Adam M. Deane
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1704154
Subject(s) - medicine , vasodilation , angiotensin ii , shock (circulatory) , cardiology , blood pressure
Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom